Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Lambertini

Showing results (311-320 of 375) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2018
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level DataMatteo Lambertini, Halle C F Moore, Robert C F Leonard, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
The Lancet. Oncology|October 5, 2023
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statementWanda Cui, Rodney P Rocconi, Ramya Thota, et al.
Cancer Treatment Reviews|June 19, 2023
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysisCarlotta Becherini, Luca Visani, Saverio Caini, et al.
Eclinicalmedicine|April 30, 2024
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trialsEva Blondeaux, Wanling Xie, Luca Carmisciano, et al.
Breast (Edinburgh, Scotland)|June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidenceRodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
Breast Cancer Research and Treatment|December 28, 2017
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)Noam Ponde, Ian Bradbury, Matteo Lambertini, et al.
The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.
Clinical Breast Cancer|June 7, 2025
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International StudySoraia Lobo-Martins, Veronique Debien, Elisa Agostinetto, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2026
Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studiesSimone Nardin, Marco Bruzzone, Luca Arecco, et al.
Pageof 38

Showing results (311-320 of 375) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2018
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level DataMatteo Lambertini, Halle C F Moore, Robert C F Leonard, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
The Lancet. Oncology|October 5, 2023
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statementWanda Cui, Rodney P Rocconi, Ramya Thota, et al.
Cancer Treatment Reviews|June 19, 2023
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysisCarlotta Becherini, Luca Visani, Saverio Caini, et al.
Eclinicalmedicine|April 30, 2024
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trialsEva Blondeaux, Wanling Xie, Luca Carmisciano, et al.
Breast (Edinburgh, Scotland)|June 29, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidenceRodrigo Sanchez-Bayona, Carey Anders, Rupert Bartsch, et al.
Breast Cancer Research and Treatment|December 28, 2017
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)Noam Ponde, Ian Bradbury, Matteo Lambertini, et al.
The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.
Clinical Breast Cancer|June 7, 2025
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International StudySoraia Lobo-Martins, Veronique Debien, Elisa Agostinetto, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2026
Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studiesSimone Nardin, Marco Bruzzone, Luca Arecco, et al.
Pageof 38